Business Description
Invion Limited is an Australian clinical-stage life sciences company focused on developing its Photosoft technology to treat cancers, infectious diseases, and atherosclerosis. Its lead product, IVX-PDT, is a light-activated compound being tested against a broad range of conditions, including skin, prostate, lung, and ovarian cancers, as well as human papillomavirus. The company is running clinical trials for its INV043 compound in prostate cancer and non-melanoma skin cancer, among other indications. Founded in 2000 and based in Melbourne, Invion works alongside research partners including the Hudson Institute of Medical Research and the Peter MacCallum Cancer Centre.
